Hong Kong-based Hutchmed (China) Ltd. saw its US sales of the cancer drug Fruzaqla jump nearly 53% in the second quarter, driven by strong market uptake. While this boosted overall revenue, Hutchmed’s net profits fell due to a high base effect from a lucrative licensing deal the previous year. Despite this, the company is optimistic about its future, focusing on innovative drugs and considering divesting its traditional Chinese medicine business.